India plans a dedicated bulk drug wholesale licence: the Union Health Ministry on 19 November 2026 released draft rules, notified as G.S.R. 987(E), that would require wholesalers of active pharmaceutical ingredients (APIs), other bulk substances and key raw materials to hold a licence separate from the one used to trade finished medicines. The amendment to the Drugs Rules, 1945 introduces new application and licence forms, brings narcotic and psychotropic bulk drugs inside the same framework, and gives the public 30 days to object or suggest changes.
Key takeaways on the bulk drug wholesale licence
- Today one common wholesale licence covers both formulations and bulk drugs; the draft splits them.
- New Form 19-BC (application) and Form 20-BC (licence) would apply only to bulk drug sales.
- Bulk drug sales must happen under the personal supervision of a competent person.
- Bulk drugs covered by the NDPS Act, 1985 fall within the new licence.
- Existing licensees get until their current retention period ends or 12 months after final notification, whichever is later.
- Objections and suggestions are open for 30 days after the gazette copies are made public.
Why the government is separating bulk drugs
Bulk drugs are the raw active and inactive substances that manufacturers turn into tablets, syrups and injections. Under the current system, a trader who holds a wholesale licence for finished medicines can also sell these ingredients, with no separate record of who bought what grade of material for which purpose. Regulators have argued for years that this blind spot makes it hard to trace substandard or diverted raw materials.
The ministry says the change will give it better control over wholesale bulk drug sales, sharper enforcement against antimicrobial resistance (by tracking where antibiotic APIs end up) and tighter monitoring of narcotic and psychotropic substances. Business Standard linked the proposal to the oversight gaps exposed by deaths from cough syrups contaminated with diethylene glycol, where investigators struggled to trace industrial-grade solvents sold as pharmaceutical-grade excipients. The draft itself frames the aim as supply-chain accountability.
The idea is not new. The Drugs Consultative Committee agreed to it at its 67th meeting on 17 November 2025, and the Drugs Technical Advisory Board endorsed it at its 93rd meeting on 16 February 2026.
Current rules versus the draft
| Area | Today | Under the draft |
|---|---|---|
| Licence scope | One wholesale licence for formulations and bulk drugs | Separate licence for bulk drugs |
| Forms | Existing wholesale forms | New Form 19-BC (application) and Form 20-BC (licence) |
| Supervision | General wholesale requirements | Bulk sales under personal supervision of a competent person |
| NDPS bulk drugs | Handled under general rules | Expressly covered by the bulk licence |
| Transition | Not applicable | Later of retention-period expiry or 12 months after final rules |
One detail still unclear is who qualifies as a competent person. An unnamed official told Business Standard that a science graduate with two years of experience handling such materials, or a registered pharmacist, could qualify. That has not been confirmed in the published reports of the draft, so traders should check the gazette text.
Who will feel it first
The biggest change falls on traders and distributors that sit between API makers and formulation units, a busy segment in hubs such as Hyderabad, Ahmedabad, Mumbai and Baddi. They will need to apply for the new licence, appoint a qualified supervisor and keep bulk drug records apart from finished-product records. Small formulators that buy APIs through these traders should expect more paperwork in purchase documents but also cleaner audit trails, which matter during inspections by Indian and foreign regulators.
The draft arrives the same week the ministry proposed Good Storage and Distribution Practices rules for medicines; see our report on the GSDP draft rules and Schedule M relief. It also lands as the US FDA steps up surprise inspections of Indian plants, covered in our piece on FDA unannounced inspections in India. Read more in our Pharmaceutical section.
Market context
The stakes are global. Acumen Research and Consulting estimates the active pharmaceutical ingredient market at USD 255.47 billion in 2025, rising to USD 473.20 billion by 2035 at a 6.3% CAGR. Asia-Pacific held about 25% of the market in 2025 and is expected to post the fastest growth, at an 8.5% CAGR, while merchant API suppliers, the companies that sell ingredients to other drugmakers, held 58% share. For India, a major supplier in that merchant trade, traceable distribution is increasingly a condition of keeping export customers.
What happens next
- The 30-day consultation runs from the date gazette copies are made available; industry bodies are likely to seek clarity on supervisor qualifications and record formats.
- The ministry will then issue final rules, possibly with changes.
- State drug controllers, who issue wholesale licences, will need procedures and fees for the new forms.
- Licensees then have at least 12 months to comply.
FAQ
What is the new bulk drug wholesale licence in India?
It is a proposed licence, under draft amendments to the Drugs Rules, 1945, that wholesalers would need specifically to sell bulk drugs such as APIs. Finished medicines would stay under the existing wholesale licence.
When will the separate bulk drug licence apply?
Not yet. The rules are in draft. Once finalised, existing licensees must comply when their current retention period ends or 12 months after final publication, whichever is later.
Which forms are proposed for the bulk drug licence?
The draft introduces Form 19-BC for applying and Form 20-BC for the licence itself.
How can I send comments on the draft?
Objections and suggestions go to the Under Secretary (Drugs), Ministry of Health and Family Welfare, Kartavya Bhawan-1, New Delhi, within 30 days of the gazette being made public. Check the official gazette for the exact email address.
Sources: Ministry of Health and Family Welfare draft notification G.S.R. 987(E) as reported by ANI and Business Standard (19 November 2026). Market data: Acumen Research and Consulting. This article is for information only and is not legal or regulatory advice. Last updated 19 November 2026.
